Type 1 diabetes mellitus and physical activity, the possibilities of using insulin degludec: analysis of clinical cases
- Authors: Elsukova O.S.1,2
-
Affiliations:
- Kirov State Medical University
- Kirov Clinical Hospital No. 7 named after V.I. Yurlova
- Issue: Vol 32, No 2 (2025)
- Pages: 129-135
- Section: Clinical case
- URL: https://journals.rcsi.science/2073-4034/article/view/294228
- DOI: https://doi.org/10.18565/pharmateca.2025.2.129-135
- ID: 294228
Cite item
Open Access
Access granted
Subscription Access
Abstract
Regular physical activity is an integral part of the life of patients with type 1 diabetes mellitus (DM1) due to their young age. Regular aerobic physical activity is associated with improved overall well-being and is a method of preventing cardiovascular diseases. An increased risk of nocturnal hypoglycemia after physical activity is a factor limiting physical activity, especially in young patients and children. Insulin degludec is an analogue of long-acting basal insulin (with a duration of action of more than 42 hours), which has a low variability of action. The ADREM study, conducted using continuous glucose monitoring systems, demonstrated that afternoon aerobic exercise in patients with DM1 treated with insulin degludec did not affect the risk of subsequent nocturnal hypoglycemia. This article reviews a case series of patients with DM1 treated with insulin degludec and regularly engaged in physical activity.
Full Text
##article.viewOnOriginalSite##About the authors
Olga S. Elsukova
Kirov State Medical University; Kirov Clinical Hospital No. 7 named after V.I. Yurlova
Author for correspondence.
Email: oselsukova@mail.ru
ORCID iD: 0000-0002-2341-9491
Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy, Head of the Endocrinology Department, Regional Endocrinology Center
Russian Federation, Kirov; KirovReferences
- Chimen M., Kennedy A., Nirantharakumar K., et al. Whatarethehealthbenefits ofphysical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 2012;55(3):542–51. doi: 10.1007/s00125-011-2403-2.
- Metcalf K.M., Singhvi A., Tsalikian E., et al. Effects of moderate-to-vigorous intensity physical activity on overnight and next-day hypoglycemia in active adolescents with type 1 diabetes. Diab Care. 2014;37(5):1272–8. doi: 10.2337/dc13 1973.
- McMahon S.K., Ferreira L.D., Ratnam N., et al. Glucose requirements to maintain euglycemia after moderate-intensity after noon exercise in adolescents with type 1 diabetes are increased in a biphasic manner. J Clin Endocrinol Metab. 2007;92(3):963–8. doi: 10.1210/jc.2006-2263.
- Gomez A.M., Gomez.C., Aschner P., et al. Effects of perform ing morning versus afternoon exercise on glycemic control and hypoglycemia frequency in type 1 diabetes patients on sensor augmented insulin pump therapy. J Diabetes Sci Technol. 2015;9(3):619–24. doi: 10.1177/1932296814566233.
- Graveling A.J., Frier B.M. The risks of nocturnal hypoglycaemia in insulin-treated diabetes. Diabetes Res Clin Pract. 2017133:30–9. doi: 10.1016/j.diabres.2017.08.012.
- Campbell M.D., Walker M., Bracken R. Insulintherapy and dietary adjustments to normalize glycemia and prevent noctur nal hypoglycemia after evening exercise in type 1 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2015;3(1):e000085. doi: 10.1136/bmjdrc-2015-000085.
- Heise T., Hermanski L., Nosek L., et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diab Obes Metab. 2012;14(9):859–64. doi: 10.1111/j.1463-1326.2012.01627.x.
- Drenthen L.C.A., Ajie M., Abbink E.J., et al. No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study. Diabetologia. 2023;66(6):1035–44. doi: 10.1007/s00125-023-05893-9.
- Wysham C.., Bhargava A, Chaykin L., et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes. JAMA. 2017;318(1):45. doi: 10.1001/jama.2017.7117.
- Liu W., Yang X., Huang J. Efficacy and safety of insulin degludec versus insulin glargine: A systematic review and meta-analysis of fifteen clinical trials. Int J Endocrinol. 2018;2018(2):1–10. doi: 10.1155/2018/8726046.
- Ratner R.E., Gough S.C.L., Mathieu C., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diab Obes Metab. 2013;15(2):175–84. doi: 10.1111/dom.12032.
Supplementary files
